QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • XOMA Corp. (XOMA) Reveals Manufacturing Agreement With Boehringer Ingelheim 0 comments
    Aug 3, 2012 1:39 PM | about stocks: XOMA

    2012 XOMA is a biopharmaceutical company that combines a portfolio of innovative therapeutic antibodies, both in preclinical research and late-stage clinical development, with its recently launched commercial operations. The company focuses its antibody research and development on allosteric modulation, which offers opportunities for new classes of therapeutic antibodies to treat a broad range of diseases.

    The company announced that it has entered into an agreement with its partner, Les Laboratories Servier, and Boehringer Ingelheim to transfer XOMA's technology and process for the commercial manufacture of gevokizumab, its novel interleukin 1-beta allosteric modulating antibody. Gevokizumab is currently in Phase 3 clinical development in patients with non-infectious uveitis, an inflammatory disease of the uvea, involving the intermediate and/or posterior segment of the eye. Financial terms of the deal between all the parties were not disclosed.

    Upon completion of the transfer and the establishment of biological comparability, Boehringer is expected to produce givokizumab at its facility in Biberach, Germany, for XOMA's commercial use. XOMA and Servier will retain all rights to the development and commercialization of givokizumab. The German company has more than 35 years of expertise in the area of manufacturing monoclonal antibodies on a commercial scale.

    Other products in XOMA's pipeline include the XMet Program, which is comprised of three classes of preclinical antibodies, including Selective Insulin Receptor Modulators (SIRMs) that could be important in the future treatment of diabetes. For additional information about XOMA and all its products, please visit the company's website at xoma.com.

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: XOMA
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.